• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » med fusion expands solid tumor profiling services

med fusion expands solid tumor profiling services

January 22, 2015
CenterWatch Staff

med fusion, an integrated Molecular Center of Excellence and clinical trials service organization headquartered in Lewisville, Texas, has released its solid tumor molecular profiling testing services (SEQ) enhanced by next generation sequencing (NGS) technology. The introduction of NGS will further enable physicians to interrogate their patient’s tumor at the molecular level in order to develop a personalized treatment plan according to the genetic makeup of their specific tumor.

With integrated and comprehensive testing services, med fusion offers both disease-specific panels (LUNGSEQ, COLONSEQ, COLONSEQPlus) for prioritizing treatment options within standard of care guidelines as well as a hot spot cancer panel (50SEQ) by NGS to support treatment options for rare, refractory or recurrent disease. The SEQ testing results associate therapy options based upon FDA, NCCN and ASCO guidelines in a complete and tailored report for the patient and physician.

“Genome-based testing is a more targeted and efficient strategy for physicians to identify and treat mutations that may be driving tumor growth,” said Dr. Raul Benavides, chief medical officer, med fusion. “Our Solid Tumor Program will continue to build upon these strategies that we have implemented for lung and colon cancers. By 2016, med fusion’s solid tumor program will expand to include molecular profiling services for melanoma, glioma, breast and ovarian cancers.”

Aligned with its personalized and comprehensive approaches, med fusion is in network with most private and government insurance providers, and also has available flexible and reflexive molecular profiling algorithms to meet the clinical needs and cost efficiencies for physicians and patients.

“Striving to ensure every patient receives the best health care, we recognize the need to participate in the health plans of our client’s patient population,” states Jon Hart, CEO, med fusion. “As a result, med fusion is a participating provider with most national managed care organizations, as well as, regional and state healthcare insurers. Being a participating provider allows us to offer the most cost efficient testing services to our patients.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing